Product Center
2024-2025 Flu Season HRK-X Approved for Signing On
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-12
- Views:
(Summary description)On June 12, 2024, China Wisdom Bio's quadrivalent influenza virus subunit vaccine HRK-X for the 2024-2025 influenza season received the Certificate of Approval and Issue of Biological Products issued by the State Drug Administration, which is still exclusive in China, and will be quickly dispatched to the whole country to guard the health of the Chinese people.
2024-2025 Flu Season HRK-X Approved for Signing On
(Summary description)On June 12, 2024, China Wisdom Bio's quadrivalent influenza virus subunit vaccine HRK-X for the 2024-2025 influenza season received the Certificate of Approval and Issue of Biological Products issued by the State Drug Administration, which is still exclusive in China, and will be quickly dispatched to the whole country to guard the health of the Chinese people.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-12 17:31
- Views:
On June 12, 2024, China Wisdom Bio's quadrivalent influenza virus subunit vaccine HRK-X for the 2024-2025 influenza season received the Certificate of Approval and Issue of Biological Products issued by the State Drug Administration, which is still exclusive in China, and will be quickly dispatched to the whole country to guard the health of the Chinese people.
As a new third-generation influenza vaccine, the quadrivalent influenza virus subunit vaccine HRK-X has its unique extraction process of influenza virus subunits (HA: hemagglutinin and NA: neuraminidase), which ensures the high purity of the HA and NA content of the vaccine strain (more than 85%) and vaccine safety, while at the same time exerting good immunogenicity. Many of the quality standards of the product are higher than those of the Chinese and EU Pharmacopoeias and have reached the international advanced level.
The approval and listing of HRK-X will provide a better choice for vaccination in the 2024-2025 influenza season and help influenza prevention and control.
According to statistics, 12.52 million cases of influenza were reported in China in 2023, which is 5.1 times more than that in 2022.
Influenza (referred to as “influenza”) is an acute respiratory infectious disease caused by influenza virus, which is a serious health hazard to humans. Influenza viruses are antigenically variable and spread rapidly, causing seasonal epidemics every year, and outbreaks are easy to occur in places where people gather, such as schools, childcare institutions and nursing homes. The population is generally susceptible to influenza virus, and the risk groups such as pregnant women, infants and young children, the elderly, and patients with chronic diseases are more seriously jeopardized by influenza infection. According to data from the CDC's infectious disease report: in 2023, the annual number of reported influenza cases exceeded 10 million, reaching 12.52 million cases, which is 5.1 times the number in 2022. The World Health Organization Influenza Vaccine Position Paper (2022 Edition) and the China Influenza Vaccination Technical Guidelines (2023-2024) both point out that annual influenza vaccination is an effective means of preventing influenza, and can significantly reduce the risk of influenza and serious complications for those who are vaccinated.
Relevant information
-
Influenza virus subunit vaccine (adjuvant) IND application approvedRecently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) jointly applied for a Class I new drug "Influenza Virus Subunit Vaccine (Adjuvant)" IND application, which has been approved by the Drug Evaluation Center (CDE) of the China National Medical Products Administration. The approval of this vaccine marks the completion of the full coverage of the company's subunit influenza vaccine product pipeline for trivalent and quadrivalent influenza virus subunit vaccines, providing the most accurate selection for different age groups and different demand groups. - The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
- Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
